Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Clinical Free

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

White House

The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document

News Analysis

NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science

Capitol Hill

NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing

Cancer Policy

AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG

HHS ordered to cut 35% of spending on contracts

National Cancer Registrars Association launches campaign to protect U.S. cancer registries

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

HHS said it would terminate Women’s Health Initiative, then reconsidered

DOJ letters to peer-reviewed journals allege partisan bias in medical literature

Clinical Roundup

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

UC Lung Cancer Consortium and AstraZeneca partner to improve early lung cancer detection

In The Clinic

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

Free Trials & Tribulations

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

Trials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Latest Issue

Read the latest issue

DOWNLOAD THE PDF

NEWS ALERTS

Stay up to date on the latest news in oncology by joining our mailing list.

UPCOMING EVENTS

May 2025

2025 AAADV Workshop

23rd Cancer Center Summit: Accelerating Innovation in Oncology through AI

2025 ASCO Annual Meeting

View All Events

Conversations with The Cancer Letter

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Contributors

Betty Ferrell, PhD, MSN, CHPN

Advancing quality of life in oncology: A journey of compassion and innovation

W. Kimryn Rathmell, MD, PhD, MMHC

In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same

Suresh S. Ramalingam, MD

Ci4CC’s 23rd Cancer Center Summit to focus on accelerating oncology innovation through AI

Mustafa Raoof, MD

Advancing peritoneal oncology: Innovations in surgical strategies and research

Trending Stories

NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science
NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing
The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document
TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?
AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG

Recent Issues

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document

NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science

NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing

AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG

HHS ordered to cut 35% of spending on contracts

National Cancer Registrars Association launches campaign to protect U.S. cancer registries

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

HHS said it would terminate Women’s Health Initiative, then reconsidered

DOJ letters to peer-reviewed journals allege partisan bias in medical literature

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

UC Lung Cancer Consortium and AstraZeneca partner to improve early lung cancer detection

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Betty Ferrell, PhD, MSN, CHPN

W. Kimryn Rathmell, MD, PhD, MMHC

Suresh S. Ramalingam, MD

Mustafa Raoof, MD

Never miss an issue!

Login

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising recordCurrent record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Never miss an issue!

Login

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed